Why adding biologics changes the conversation with your carrier
A malpractice policy written for a clinic's existing scope of practice does not automatically anticipate a new product category. Before ordering perinatal tissue or exosome products, it is worth confirming with your carrier whether their use fits within your current policy or requires an endorsement, a disclosure, or a separate conversation.
This is not a product-specific question your supplier can answer. It depends on your policy language, your state, and your scope of practice, which means it belongs with your broker or carrier directly, not with marketing material from a vendor.
Questions worth raising with your carrier before you order
Carriers and policies vary enough that a general answer is not useful here. The goal of this conversation is to remove ambiguity before the first patient is treated, not after a claim is filed.
- Does our current policy cover procedures using these product categories, or is an endorsement needed?
- Does the carrier require disclosure of new product lines as part of ongoing coverage?
- Are there documentation requirements, such as informed consent language, that affect how a claim would be evaluated?
- Does coverage differ depending on whether the product is a tissue allograft or an exosome preparation?
Informed consent as a risk management practice, not just a form
Consent documentation should reflect what the patient was actually told. These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice. The decision to use the product, and any clinical rationale, rests with the treating physician. Ask the carrier and counsel what consent and product records apply to the specific policy and practice, and keep relevant records retrievable.
This documentation supports the clinic's own compliance posture. Keep consent records organized alongside the lot-traceability record for the product used, so the two can be retrieved together.
Vendor documentation your insurer or counsel may ask for
In the event of a claim or inquiry, ask your carrier and counsel which records are relevant. Clinics should already be keeping lot-specific certificates of analysis, the supplier's description of its donor screening and release testing process, and any characterization or ingredient disclosure the supplier provides to verified accounts.
A clinic that can produce this documentation on request is in a materially different position than one that cannot, independent of anything about the underlying event. Treat vendor documentation as part of your risk file, not as something you request only if asked.
Marketing claims as an insurance and liability issue, not just a regulatory one
Claims about disease benefit, healing, or outcomes create regulatory exposure, as described elsewhere in this resource library, but they also create liability exposure that is distinct from the product itself. A patient's expectations, shaped by what a clinic published, can become relevant if an outcome is disputed, regardless of what the product's documentation actually supports.
Aligning your marketing review process with your malpractice risk management is more efficient than treating them as separate exercises, since the same content, claims about what a product does for a condition, is the common thread in both.
Building a risk file before you launch, not after
Assemble this before the first order, not reactively. This article is educational and is not legal or insurance advice; confirm your specific coverage and documentation requirements with your carrier and your own counsel.
- Written confirmation from your carrier on coverage for this product category
- Consent documentation specific to these products, not a generic form
- Current vendor and lot documentation on file
- A marketing review process tied to your compliance checklist
- A point of contact (medical director or compliance lead) responsible for the file
Frequently asked questions
Will our existing malpractice policy automatically cover procedures using these products?+
Not necessarily. Confirm directly with your carrier or broker whether your current policy covers this product category or requires an endorsement or disclosure. This is a policy-specific question, not a general one.
Does informed consent reduce our liability exposure?+
Thorough, product-specific informed consent is a recognized risk management practice, but it is not a guarantee against a claim. It does create a clear record of what the patient was told, which matters if an outcome is later disputed.
What vendor documentation should we keep on file in case of a claim?+
Lot-specific certificates of analysis, the supplier's donor screening and release testing description, and any characterization or ingredient disclosure provided to verified accounts. Keep these organized by lot alongside your consent and patient-use records.
Should we talk to an attorney before adding these products?+
Yes. This article is educational and is not legal advice. Regulatory and liability exposure depends on your state, your policy, and your marketing, and a review with counsel before launch is more useful than addressing it after a claim or inquiry.